INTEGA SUNITINIB 12.5mg Hard Capsule

Manufacturer
Remedica Ltd.(CYPRUS)

Registraction Number
MAL24086019ACZ

Content:
INTEGA SUNITINIB 12.5 mg Hard Capsules contain 12.5 mg of sunitinib as the active ingredient. Sunitinib is a protein kinase inhibitor used to treat various types of cancer by preventing the activity of proteins involved in the growth and spread of cancer cells.
Indications:
INTEGA SUNITINIB is indicated for:

• Gastrointestinal Stromal Tumors (GIST): For patients whose disease has progressed on or who are intolerant to imatinib.
• Advanced Renal Cell Carcinoma (RCC): For patients with metastatic RCC.
• Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors (pNET): For patients with unresectable locally advanced or metastatic disease.

• Dosage: The recommended dose for GIST and advanced RCC is 50 mg orally once daily for 4 weeks, followed by a 2-week rest period. For pNET, the dose is 37.5 mg orally once daily continuously without a scheduled off-treatment period.
• Administration: Take the capsule with water. It can be taken with or without food.
• Consistency: Take the medication at the same time each day to help you remember.
• Precautions: Inform your doctor if you have any history of liver disease, heart problems, or if you are pregnant, planning to become pregnant, or breastfeeding.